Brittney P Ciszek1, Sandra C O'Buckley, Andrea G Nackley. 1. From the Dental Research Department, Center for Pain Research and Innovation, University of North Carolina, Chapel Hill, North Carolina. Current affiliation: Center for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina (A.G.N.).
Abstract
BACKGROUND: Patients with chronic pain disorders exhibit increased levels of catecholamines alongside diminished activity of catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines. The authors found that acute pharmacologic inhibition of COMT in rodents produces hypersensitivity to mechanical and thermal stimuli via β-adrenergic receptor (βAR) activation. The contribution of distinct βAR populations to the development of persistent pain linked to abnormalities in catecholamine signaling requires further investigation. METHODS: Here, the authors sought to determine the contribution of peripheral, spinal, and supraspinal βARs to persistent COMT-dependent pain. They implanted osmotic pumps to deliver the COMT inhibitor OR486 (Tocris, USA) for 2 weeks. Behavioral responses to mechanical and thermal stimuli were evaluated before and every other day after pump implantation. The site of action was evaluated in adrenalectomized rats receiving sustained OR486 or in intact rats receiving sustained βAR antagonists peripherally, spinally, or supraspinally alongside OR486. RESULTS: The authors found that male (N = 6) and female (N = 6) rats receiving sustained OR486 exhibited decreased paw withdrawal thresholds (control 5.74 ± 0.24 vs. OR486 1.54 ± 0.08, mean ± SEM) and increased paw withdrawal frequency to mechanical stimuli (control 4.80 ± 0.22 vs. OR486 8.10 ± 0.13) and decreased paw withdrawal latency to thermal heat (control 9.69 ± 0.23 vs. OR486 5.91 ± 0.11). In contrast, adrenalectomized rats (N = 12) failed to develop OR486-induced hypersensitivity. Furthermore, peripheral (N = 9), but not spinal (N = 4) or supraspinal (N = 4), administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A blocked the development of OR486-induced hypersensitivity. CONCLUSIONS: Peripheral adrenergic input is necessary for the development of persistent COMT-dependent pain, and peripherally-acting βAR antagonists may benefit chronic pain patients.
BACKGROUND:Patients with chronic pain disorders exhibit increased levels of catecholamines alongside diminished activity of catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines. The authors found that acute pharmacologic inhibition of COMT in rodents produces hypersensitivity to mechanical and thermal stimuli via β-adrenergic receptor (βAR) activation. The contribution of distinct βAR populations to the development of persistent pain linked to abnormalities in catecholamine signaling requires further investigation. METHODS: Here, the authors sought to determine the contribution of peripheral, spinal, and supraspinal βARs to persistent COMT-dependent pain. They implanted osmotic pumps to deliver the COMT inhibitor OR486 (Tocris, USA) for 2 weeks. Behavioral responses to mechanical and thermal stimuli were evaluated before and every other day after pump implantation. The site of action was evaluated in adrenalectomized rats receiving sustained OR486 or in intact rats receiving sustained βAR antagonists peripherally, spinally, or supraspinally alongside OR486. RESULTS: The authors found that male (N = 6) and female (N = 6) rats receiving sustained OR486 exhibited decreased paw withdrawal thresholds (control 5.74 ± 0.24 vs. OR486 1.54 ± 0.08, mean ± SEM) and increased paw withdrawal frequency to mechanical stimuli (control 4.80 ± 0.22 vs. OR486 8.10 ± 0.13) and decreased paw withdrawal latency to thermal heat (control 9.69 ± 0.23 vs. OR486 5.91 ± 0.11). In contrast, adrenalectomized rats (N = 12) failed to develop OR486-induced hypersensitivity. Furthermore, peripheral (N = 9), but not spinal (N = 4) or supraspinal (N = 4), administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A blocked the development of OR486-induced hypersensitivity. CONCLUSIONS: Peripheral adrenergic input is necessary for the development of persistent COMT-dependent pain, and peripherally-acting βAR antagonists may benefit chronic painpatients.
Authors: Mohan R Dasu; Sandra R Ramirez; Thi Dinh La; Farzam Gorouhi; Chuong Nguyen; Benjamin R Lin; Chelcy Mashburn; Heather Stewart; Thomas R Peavy; Jan A Nolta; Roslyn R Isseroff Journal: Stem Cells Transl Med Date: 2014-04-23 Impact factor: 6.940
Authors: F Ochoa-Cortes; R Guerrero-Alba; E E Valdez-Morales; I Spreadbury; C Barajas-Lopez; M Castro; J Bertrand; N Cenac; N Vergnolle; S J Vanner Journal: Neurogastroenterol Motil Date: 2013-11-29 Impact factor: 3.598
Authors: Y Claustre; M Leonetti; V Santucci; I Bougault; C Desvignes; L Rouquier; N Aubin; P Keane; S Busch; Y Chen; V Palejwala; M Tocci; P Yamdagni; M Didier; P Avenet; G Le Fur; F Oury-Donat; B Scatton; R Steinberg Journal: Neuroscience Date: 2008-07-11 Impact factor: 3.590
Authors: Adelina Holguin; Kevin A O'Connor; Joseph Biedenkapp; Jay Campisi; Julie Wieseler-Frank; Erin D Milligan; Michael K Hansen; Leah Spataro; Elena Maksimova; Courtenay Bravmann; David Martin; Monika Fleshner; Steven F Maier; Linda R Watkins Journal: Pain Date: 2004-08 Impact factor: 6.961
Authors: Adley Tsang; Michael Von Korff; Sing Lee; Jordi Alonso; Elie Karam; Matthias C Angermeyer; Guilherme Luiz Guimaraes Borges; Evelyn J Bromet; K Demytteneare; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Jean-Pierre Lepine; Josep Maria Haro; Daphna Levinson; Mark A Oakley Browne; Jose Posada-Villa; Soraya Seedat; Makoto Watanabe Journal: J Pain Date: 2008-07-07 Impact factor: 5.820
Authors: Andrea Gail Nackley; Kai Soo Tan; Karamarie Fecho; Patrick Flood; Luda Diatchenko; William Maixner Journal: Pain Date: 2006-11-07 Impact factor: 7.926
Authors: Xin Zhang; Jane E Hartung; Andrey V Bortsov; Seungtae Kim; Sandra C O'Buckley; Julia Kozlowski; Andrea G Nackley Journal: Brain Behav Immun Date: 2018-06-20 Impact factor: 7.217
Authors: G D Slade; R B Fillingim; R Ohrbach; H Hadgraft; J Willis; S J Arbes; I E Tchivileva Journal: J Dent Res Date: 2020-10-08 Impact factor: 6.116
Authors: Inna E Tchivileva; Holly Hadgraft; Pei Feng Lim; Massimiliano Di Giosia; Margarete Ribeiro-Dasilva; John H Campbell; Janet Willis; Robert James; Marcus Herman-Giddens; Roger B Fillingim; Richard Ohrbach; Samuel J Arbes; Gary D Slade Journal: Pain Date: 2020-08 Impact factor: 7.926
Authors: William C Hedderson; Paul A Borsa; Roger B Fillingim; Stephen A Coombes; Chris J Hass; Steven Z George Journal: Clin J Pain Date: 2020-10 Impact factor: 3.423